Cholangiocarcinoma is bile duct cancer, an adenocarcinoma arising from the biliary epithelium that can occur intrahepatically or extrahepatically. It is often diagnosed at advanced stages and generally has poor prognosis.
The FDA has granted Priority Review for lirafugratinib, an FGFR2 inhibitor for second-line cholangiocarcinoma treatment, with a PDUFA date of September 27, 2026. Clinical trial data showed a 46.5% objective response rate and 11.8-month median duration of response. The therapy demonstrated a manageable safety profile with lower rates of common FGFR inhibitor side effects.
Mayo Clinic is pursuing two distinct nanoparticle-based cancer treatments: milk-derived nanoparticles for targeted gene therapy in bile duct cancer, and magnetic nanoparticle hyperthermia for metastatic solid tumors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598318 |
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07594067 |
TCR1188-ABC Cells in KRAS-mutated Cancers |
NOT_YET_RECRUITING | PHASE1 |
| NCT07561775 |
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07558304 |
Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial) |
NOT_YET_RECRUITING | NA |
| NCT07557225 |
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors |
RECRUITING | NA |
| NCT07556835 |
Outcomes After Liver and Biliary Resection at a High-Volume Center |
NOT_YET_RECRUITING | |
| NCT07514533 |
The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07486713 |
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies |
RECRUITING | PHASE4 |
| NCT07478523 |
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers |
RECRUITING | PHASE2 |
| NCT07454486 |
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort |
NOT_YET_RECRUITING |
